Marcus Roberts
Hospice and Palliative Medicine · Tifton, GANPI 1699731026
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Novo Nordisk at 26.5% of the total. Reporting peaked in 2019 at $338 and has fallen 84.1% since, to $54 in 2025.
Across 58 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$249
- Astellas Pharma US Inc$99
- GSK$64
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$63
- Lilly USA, LLC$61
- Amgen$42
- plus $361 from 15 others
What the payments were for
- Food & beverage$939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $249 |
| Astellas Pharma US Inc | 5 | $99 |
| GSK | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $63 |
| Lilly USA, LLC | 4 | $61 |
| Amgen | 3 | $42 |
| Merck | 3 | $39 |
| Valeritas, Inc. | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $33 |
| AbbVie | 2 | $33 |
| Ultragenyx Pharmaceutical Inc. | 2 | $26 |
| Novartis | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| IBSA Pharma Inc. | 1 | $12 |
How this compares
$939 in reported general payments places this provider in the 80th percentile of 69 hospice and palliative medicine providers in Georgia.
See all hospice and palliative medicine providers in Georgia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 27 | $19,981 |
| EliquisApixaban | 26 | $18,349 |
| XareltoRivaroxaban | 15 | $12,358 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $7,459 |
| RytaryCarbidopa/Levodopa | 12 | $5,513 |
| Gabapentin | 176 | $1,945 |
| Novolog FlexpenInsulin Aspart | 14 | $1,901 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $1,601 |
| Omeprazole | 71 | $1,296 |
| Atorvastatin Calcium | 167 | $960 |
| FenofibrateFenofibrate Nanocrystallized | 19 | $912 |
| Liothyronine Sodium | 11 | $752 |
| Fluticasone Propionate | 44 | $644 |
| Buspirone Hcl | 34 | $638 |
| Lisinopril | 116 | $606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $18,34926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 69 hospice and palliative medicine providers in Georgia.
Other hospice and palliative medicine in Tifton
- Veronica SudekumWarner Robins$7K
- Anthony EkwenchiAustell$5K
- Joshua JacksonAtlanta$5K
- Nokuthula MsimangaMarietta$3K
- Halima DaboikoKennesaw$3K
- Michelle ParkMarietta$2K
- Olumuyiwa AdeboyeLagrange$2K
- Mary KeithGainesville$2K
- Tanya NikolovaMarietta$1K
- Christina ChenMarietta$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.